The approval of semaglutide (Wegovy, 2.4mg weekly) and tirzepatide (Zepbound, up to 15mg weekly) for chronic weight management has been described as the most significant advance in obesity medicine since bariatric surgery — achieving weight loss outcomes that were previously only possible with surgical intervention, now through pharmacological mechanisms that target the fundamental neurobiology of appetite and energy homeostasis.
Mechanism: Why GLP-1 Agonists Are Different
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Pharmacological GLP-1 receptor agonism (with half-lives of days to weeks, versus endogenous GLP-1's 1–2 minute half-life) produces: hypothalamic appetite suppression (reduced ghrelin, increased satiety signaling), delayed gastric emptying (caloric intake reduction through early satiety), reduced hepatic glucose production, and pancreatic β-cell stimulation (glucose-dependent insulin secretion — reduced hypoglycemia risk vs. sulfonylureas). Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor co-agonism — the dual mechanism producing greater weight loss than GLP-1 alone by targeting complementary appetite pathways. The SURMOUNT-1 trial (n=2,539): tirzepatide 15mg produced 22.5% mean body weight reduction at 72 weeks — the greatest pharmacological weight loss ever recorded in an RCT. The STEP-1 trial: semaglutide 2.4mg produced 14.9% mean weight reduction at 68 weeks.
Patient Selection, Monitoring, and Clinical Use
Indication: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, OSA, ASCVD). Contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, known GLP-1 agonist hypersensitivity. Common side effects: nausea (44%), vomiting (24%), diarrhea (30%), constipation — predominantly GI and dose-dependent; minimized by slow dose titration. Pancreatitis risk: rare but monitor for symptoms. Muscle mass preservation: a significant clinical concern — 25–39% of weight lost on GLP-1 agonists is lean mass versus ~20–25% with dietary restriction alone. Resistance training and protein intake optimization (1.2–1.6g/kg/day) are recommended adjuncts. For clinical monitoring of patients on GLP-1 therapy, our diagnostic equipment section includes blood pressure monitors and metabolic monitoring tools, and our laboratory supplies support regular lipid panel and HbA1c monitoring.
